Lung cancer chemoprevention: Difficulties, promise and potential agents?

Expert Opinion on Investigational Drugs

Volumn 22, Issue 1, 2013, Pages 35-47

  Dragnev, Konstantine ^a   You, Ming ^b   Wang, Yian ^c   Lubet, Ronald ^d  

^a NORRIS COTTON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Chemopreventive agents; Lung cancer; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; BEXAROTENE; BIOLOGICAL MARKER; CETUXIMAB; CYCLIN D; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLUCOCORTICOID; ILOPROST; IMIDAZOLE; ISOTRETINOIN; KI 67 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PIOGLITAZONE; RETINOIC ACID RECEPTOR ALPHA; RETINOL; SORAFENIB; SULINDAC; TAMOXIFEN; TRITERPENOID; VANDETANIB;

APOPTOSIS; BRONCHOSCOPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; REVIEW; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LUNG NEOPLASMS; TRITERPENES;

EID: 84871001179     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.731392     Document Type: Review

References (80)

1. Fisher B, Costantino D, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. JNCI 1998;90:1371-88
2. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91
3. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011;11:13
4. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84
5. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention colorectal neoplasia: an overview. Cancer Prev Res 2012;5:164
6. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 2002;3:207-14
7. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9
8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802
9. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res 2011;4:1828-35
10. Gray J, Mao JT, Szabo E, et al. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelinesnd (2 Edition). Chest 2007;132:56S-68S
11. Omenn S, Goodman GE, Thornquist MD, et al. Effects of a combination beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5
12. Albanes D, Heinonen OP, Taylor PR et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70
13. Cohen V, Khuri FR. Chemoprevention of lung cancer: concepts and strategies. Expert Rev Anticancer Ther 2005;5:549-65
14. Hecht SS, Kassie F, Hatsukami DK. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009;9:476-88
15. Keith RL. Chemoprevention oflung cancer. Proc Am Thorac Soc 2009;6:187-93
16. Yagui-Beltran A, Jablons DM. A translational approach to lung cancer research: from EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg 2009;15:213-20
17. Wu X, Patterson S, Hawk E. Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 2011;25:445-59
18. Clark J, You M. Chemoprevention of lung cancer by tea. Mol Nutr Food Res 2006;50:144-51
19. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40
20. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007;64:1105-27
21. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55-67
22. Hecht SS, Kassie F, Hatsukami DK. Chemoprevention of lung carcinogenesis in addicted smokers and ex smokers. Nat Rev Cancer 2009;9:476-88
23. Wang Y, Rouggly L, You M, Lubet R Animal models of lung cancer characterization and use for chemoprevention research. Prog Mol Biol Transl Sci 2012;105:211-28
24. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by Vitamin A and its synthetic analogs (retinoids). Fre Proc 1976;35:1332-8
25. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB 1996;10:940-54
26. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004;17:1-16
27. Rosati R, Ramnath N, Adil MR, et al. Activity of 9cis RA and receptor selective retinoids in small cell lung cancer lines. Anticancer Res 1998;8:4071-5
28. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004;4:180-8
29. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (bexarotene): an RXR-selective ligand. Cancer Res 1996;56:5566-70
30. Grubbs CJ, Lubet RA, Atigadda VR et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2006;27:1232-9
31. Liby K, Black CC, Royce DB, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008;7:1251-7
32. Pereira MA, Kramer PM, Nines R, et al. Prevention of mouse lung tumors by bexarotene. Int J Cancer 2006;118:2359-62
33. Wang Y, Zhang R, Yao R, et al. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 2006;25:1320-9
34. Alyaquob FS, Liu Y, Tao L, et al. Modulation by bexarotene of mRNA expression of genes in mouse lung tumors. Mol Carcinog 2008;47:165-71
35. Zhang Q, Pan J, Zhang J, et al. Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice. Cancer Prev Res 2011;4:270-6
36. Wang Y, Wen W, Yi Y, et al. Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev Res 2009;2:1059-64
37. Dragnev KH, Petty WJ, Ma Y, et al. Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 2005;6:237-44
38. Dragnev KH, Petty WJ, Shah SJ, et al. A proof-of-principle clinical trial of bexarotene in patients with non small-cell lung cancer. Clin Cancer Res 2007;13:1794-800
39. Blumenschein GR Jr, Khuri FR, von Pawel J, et al. Phase III trial comparing carboplatin, paclitaxel and bexarotene with caboplatin, and paclitaxel in chemotherapy-naive patients with advanced or metastatic non small cell lung cancer. J Clin Oncol 2008;26:1879-85
40. Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2008;26:1886-92
41. Hida T, Ogawa S, Park JC, et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:17-35
42. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68
43. Hirsch FR, Bunn PA. EGFRR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-4
44. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence of the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002;8:54-60
45. Yan Y, Lu Y, Wang M, et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 2006;4:971-81
46. Lubet RA, Szabo E, Christov K, et al. Effects of Gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or bexarotene, and biomarker changes. Mol Cancer Ther 2008;7:972-9
47. Lubet RA, Lu Y, Bode AM, et al. Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers. Oncol Rep 2011;25:1389-97
48. Lu Y, Liu P, Van den Bergh F, et al. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res 2012;5:248-59
49. Dragnev KH, Ma T, Cyrus J, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res 2011;4:818
50. Lonardo F, Rusch V, Langenfeld J, et al. Overexpression ofCyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6
51. DeRoock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
52. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6
53. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
54. Dragnev KH, Petty WJ, Shah S, et al. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005;23:8757-64
55. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;12:564-71
56. Nguyen T, Sheratt PT, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003;43:233-60
57. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-β as the matchmaker. Nat Immunol 2011;12:715-22
58. Xue W, Meylan E, Oliver TG, et al. Response and resistance to NF-β inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 2011;1:236-47
59. Liby K, Risingsong R, Royce DB, et al. Triterpenoids CDDO-methylester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res 2009;2:1050-8
60. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2011;377:31-41
61. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-40
62. Mao JT, Roth MD, Fishbein MC, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res 2011;4:984-93
63. Kim ES, Hong WK, Lee JJ, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res 2010;3:148-59
64. Dupperon C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 1997;18:1001-6
65. Rioux N, Castonguay A. Prevention of NNK induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-60
66. Guttman-Yassky E, Mita A, De Jorge M, et al. Characterization of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010;46:2010-19
67. Zhang Q, Pan J, North PE, et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res 2012;5:717-25
68. Lyon CM, Klinge DM, Do KC, et al. Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 2009;30:2095-9
69. Wang Y, James M, Wen W, et al. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther 2010;9:3074-82
70. Fu H, Zhang J, Pan J, et al. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J Mice. Mol Carcinog 2011;50:913-21
71. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-81
72. Keith RL, Blatchford PJ, Kittelson J, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;4:793-802
73. Gustafson AM, Soldi R, Anderind C, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25
74. Lazzeroni M, Guerrieri-Gonzaga A Serrano D, et al. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials 2010;31:612-19
75. Veronesi G, Szabo E, Decensi A, et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res 2011;4:34-42
76. Lam S, MacAulay C, LeRiche JC, et al. Key issues in lung cancer chemoprevention trials of new agents. Recent Results Cancer Res 2003;16:182-95
77. Edell E, Lam S, Pass H, et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using flucorescence-reflection bronchoscopy an international multicenter trial. J Thorac Oncol 2009;4:49-54
78. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70
79. Wang X, Chorley BN, Pittman GS, et al. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS ONE 2010;5:11934
80. Gold KA, Kim ES, Lee J, et al. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res 2011;4:962-72